Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCRαβ+CD19+ Depleted Haploidentical HSCT Followed by Immunotherapy in Relapsed/Resistant High-risk Neuroblastoma
2024-519089-32-02Phase 2Authorised
- Sponsor
- Istituto Giannina Gaslini
- Start
- Jan 2025
- Modality
- Antibody-Based Therapeutics, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, single-arm trial of Dinutuximab beta and allogeneic peripheral blood-derived natural killer cells (CD3- CD56+) in neuroblastoma, sponsored by Istituto Giannina Gaslini. Primary endpoint: Overall Survival. Planned start Jan 2025; status: authorised.
02
Drugs
Dinutuximab betaallogeneic peripheral blood-derived natural killer cells (CD3- CD56+)
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on 2024-519089-32-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519089-32-02.